01—Abstract
Summary
Summary of the 8-K filed April 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Pfizer reported solid first-quarter 2025 results on April 29, 2025, with revenues of $13.7 billiona, down 8% reported (6% operationally) from $14.9 billion a year earlier, largely due to a roughly $1.5 billion decline in Paxlovid.
Reported diluted EPS was $0.52b versus $0.55, while Adjusted diluted EPS rose 12% to $0.92 from $0.82, supported by lower SI&A and R&D spending and a low Adjusted tax rate of 7.8%. Pfizer reaffirmed all components of its 2025 guidance, including revenues of $61.0 to $64.0 billion and Adjusted diluted EPS of $2.80 to $3.00, and said it is trending toward the upper end of the EPS range. Guidance excludes any impact from future tariff changes.
The more consequential news is the expansion of the cost realignment program. Pfizer now expects total net cost savings of about $5.7 billionc through 2027, comprising the previously stated $4.5 billion by end-2025 plus about $1.2 billion of additional SI&A savings, with one-time costs of about $1.6 billion. A separate R&D reorganization is expected to yield about $500 million in savings by end-2026, to be reinvested in the pipeline, at a one-time cost of about $600 million.
Investors should weigh these savings against roughly $2.2 billiond in total incremental one-time charges, which will weigh on GAAP results over the coming years, and note that the savings are measured against a 2023 baseline and are subject to execution risk. Capital allocation remains focused on the dividend ($2.4 billion paid in the quarter, $0.43 per share) and deleveraging, with gross leverage now below the company's target. No share repurchases have been made in 2025, and guidance assumes none.
Pfizer has $3.3 billion remaining on its repurchase authorization and retains flexibility for business development. Pfizer also fully exited its Haleon stake, generating roughly $3.3 billion in March after roughly $3.0 billion in January.
02—Key points
Key Highlights
- Q1 2025 revenues of $13.7 billion declined 8% reported and 6% operationally, driven mainly by a $1.5 billion decline in Paxlovid, partly offset by growth in Vyndaqel (+33% operationally), Comirnaty (+62%) and Nurtec ODT/Vydura (+40%).
- Adjusted diluted EPS rose 12% to $0.92, while reported diluted EPS fell 5% to $0.52, reflecting net losses on equity securities (including Haleon), higher intangible asset impairments and restructuring charges.
- 2025 guidance reaffirmed: revenues of $61.0-$64.0 billion and Adjusted diluted EPS of $2.80-$3.00, with management trending toward the upper end of the EPS range and no tariff impact assumed.
- Total expected net cost savings from the cost realignment program increased to about $5.7 billion through 2027, with $4.5 billion still on track by end-2025 and an additional $1.2 billion in SI&A savings identified.
- An expanded R&D reorganization is expected to deliver about $500 million in savings by end-2026, to be reinvested in the pipeline, with approximately $600 million in one-time costs.
- Incremental one-time costs of about $2.2 billion ($1.6 billion for SI&A savings plus $0.6 billion for R&D) will be incurred through 2027, pressuring GAAP results in the near term.
- Pfizer fully exited its Haleon stake in March 2025 for about $3.3 billion, has no 2025 buybacks planned, and retains $3.3 billion of repurchase authorization while gross leverage is below target.
03—Questions
Frequently Asked Questions
Why did Pfizer's reported revenue fall in Q1 2025?
Revenue fell 8% to $13.7 billion, mainly because Paxlovid revenue dropped about $1.5 billion (75% operationally). The decline reflects lower COVID-19 infections, the non-recurrence of a $771 million favorable adjustment recorded in Q1 2024, and lower international government purchases. Higher Medicare Part D manufacturer discounts under the Inflation Reduction Act also weighed on U.S. net pricing for products such as Eliquis, Xeljanz and Ibrance.
Did Pfizer change its 2025 earnings outlook?
No. Pfizer reaffirmed all components of its 2025 guidance, including revenues of $61.0-$64.0 billion and Adjusted diluted EPS of $2.80-$3.00. The CFO said the company is trending toward the upper end of the EPS range. The guidance does not reflect potential future tariff or trade policy changes, which management said it cannot predict.
What is the financial impact of the expanded cost realignment program?
Pfizer now expects about $5.7 billion in total net cost savings through 2027, versus a 2023 baseline. That includes $4.5 billion by end-2025 and an additional $1.2 billion in SI&A savings by 2027. The R&D reorganization adds about $500 million in savings by end-2026, reinvested in R&D. Total one-time costs are roughly $2.2 billion ($1.6 billion plus $0.6 billion), primarily severance, digital enablement and implementation, and will be incurred through 2027.
Why is reported EPS down while Adjusted EPS is up?
Reported diluted EPS fell to $0.52 from $0.55 because of net losses on equity securities (about $370 million, largely Haleon-related), higher intangible asset impairments, and restructuring charges of about $678 million. Adjusted EPS excludes amortization of intangibles, acquisition-related items, restructuring and certain significant items. Adjusted EPS rose to $0.92 from $0.82 on lower SI&A and R&D spending and a much lower Adjusted tax rate of 7.8%, versus 16.6% a year earlier.
What is Pfizer's capital return and balance sheet position?
Pfizer paid $2.4 billion in dividends ($0.43 per share) in Q1 2025 and has made no share repurchases so far this year. Guidance assumes none. The company has $3.3 billion remaining on its buyback authorization. Gross leverage is now below its stated target after the Haleon sales, and management intends to keep de-levering prudently while preserving flexibility for business development deals and possible future buybacks.
04—Continue